Home > Back to Publisher > Report Information

Pharmaceutical Pricing and Distribution in Japan: The Keys to Success in the World’s Second Largest Market

JustPharmaReports.com
June 1, 2008
110 Pages - SKU: JPM1873425

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Japan

No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere. Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders.

Whether the challenge is entering the Japanese market for the first time, moving up the all-important ranking there by market share, or negotiating with a local in-licensing partner, this report is designed to help.

New drug pricing and price revision processes explained
Written by an acknowledged expert on the Japanese market with 20 years’ experience
Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008
Incorporates all pricing rule changes that came into effect from April 2008
Pro-generic measures critically appraised
Key role of wholesalers and how they are paid clarified
Prospects for future reform to the P&R processes discussed

Executive Summary
1. Organisation & Funding of Healthcare System: 1.1 Key Actors; 1.2 Health Insurance; 1.3 Private Insurance; 1.4 Healthcare Providers; 1.5 Healthcare Benefits; 1.6 Remuneration of Providers; 1.7 Mixed Medical Care; 1.8 Healthcare Expenditure; 1.9 Pharmaceutical Costs
2. Regulatory Environment: 2.1 Intellectual Property Protection; 2.2 Regulatory Approval; 2.3 Delays in Accessing the Japanese Market; 2.4 Orphan Drugs; 2.5 National Health Insurance Reimbursement
3. Pharmaceutical Business Environment: 3.1 Market Components; 3.2 Pharmaceutical Industry; 3.3 Leading Companies; 3.4 Leading Products; 3.5 Sales and Marketing; 3.6 Formulary Access; 3.7 Consumption Tax; 3.8 Exchange Rates
4. Launch Price Setting: 4.1 Outline of Procedure; 4.2 Data Requirements; 4.3 Summary of Methodology; 4.4 Similar Efficacy Comparison Method I; 4.5 Similar Efficacy Comparison Method II; 4.6 Inter Specification Adjustment; 4.7 Inter Formulation Adjustment; 4.8 Line Extensions; 4.9 Cost Calculation; 4.10 Foreign Price Adjustment; 4.11 Role of Pharmacoeconomics; 4.12 Further Case Studies; 4.13 Sources of Price Information
5. Price Revision Process: 5.1 Drug Price Margin; 5.2 Biennial Revision; 5.3 Repricing; 5.4 Long-term Listed Brands
6. Other Cost Containment Methods: 6.1 Adjustment of Medical Fees; 6.2 Separation of Prescribing and Dispensing; 6.3 Diagnosis Procedure Combinations; 6.4 Denial of Reimbursement/Delisting; 6.5 Prescription Limitation; 6.6 Patient Copayment
7. Other Market Segments: 7.1 Generics; 7.2 Over-the-counter Medicines; 7.3 Vaccines; 7.4 Quasi Drugs
8. Distribution: 8.1 Wholesaling; 8.2 Pharmacies and Drugstores; 8.3 Mail Order/Internet Pharmacies
9. Future Prospects: 9.1 Registration; 9.2 Pricing; 9.3 Diagnosis Procedure Combinations; 9.4 Generics; 9.5 Vaccines; 9.6 Distribution
List of tables: 1.1 Japan’s healthcare in perspective; 1.2 Main health insurance schemes; 1.3 Numbers of medical institutions; 1.4 Main disease classifications of patients attending hospitals; 1.5 Growth in national medical care expenditure; 1.6 Distribution of medical care expenditure burden; 1.7 Number and share of people older than 65 years by country; 1.8 Evolution of drug cost and its share of total medical expenditure; 1.9 Per capita expenditure growth in drug costs by country; 2.1 Japan’s drug lag with specimen products; 2.2 Share of Japan-origin drugs under development by patent date; 2.3 Average time to launch foreign-origin new drugs; 2.4 Numbers of orphan drug and medical device designations; 2.5 Regulatory approval dates with specimen orphan drugs; 2.6 Numbers of drugs listed in NHI tariff; 3.1 Share of global prescription drug sales by region; 3.2 Breakdown of prescription drug market by customer group; 3.3 Top-20 pharmaceutical companies in Japan; 3.4 Leading companies in Japan by sales through wholesalers; 3.5 Share of global sales of Japanese majors by region; 3.6 Percent of company sales by portfolio age; 3.7 Key franchise sales in Japan; 3.8 Top-15 therapeutic classes in Japan; 3.9 Top-10 best-selling products in Japan; 3.10 Trends with yen exchange rate against other major currencies; 4.1 Evolution of introductory price premiums; 4.2 Numbers of new products awarded price premiums; 4.3 Examples of formulation categories for pricing purposes; 5.1 Change in drug price margin; 5.2 NHI drug price revisions since 1981; 5.3 Introductory pricing of statins; 5.4 Examples of major originator brands affected by above-average cuts; 5.5 Breakdown of price revisions by numbers of affected products; 5.6 Examples of repricing, 1996-2006; 5.7 Drugs repriced in 2008; 6.1 Growth in prescription numbers; 6.2 Share of wholesaler sales by customer group, 2006 vs 1992; 6.3 Diseases attracting a ceiling on copayment; 7.1 Growth in generic penetration; 7.2 Generic sales through wholesalers; 7.3 Consolidated sales of leading generic manufacturers; 7.4 Recent NHI price erosion with Mevalotin and generic pravastatin; 7.5 Numbers of newly listed generics; 7.6 Examples of generics newly listed in tariff; 7.7 Average OTC price build up; 7.8 International comparison of OTC prices; 7.9 International comparison of ingredient numbers in OTC brands; 7.10 Examples of ingredients recently switched to OTC; 8.1 Financial situation of wholesalers; 8.2 Bar code requirements; 8.3 Evolution and breakdown of sales by wholesalers; 8.4 Wholesaler sales by customer group; 8.5 Change in numbers of FJPWA members; 8.6 Consolidated sales of top-10 wholesalers, 2007; 8.7 Consolidated sales of top-10 wholesalers, 2000; 8.8 Manufacturer shareholdings in leading wholesalers; 8.9 Debt and credit of wholesalers; 8.10 Leading drugstore chains
List of figures: 4.1 NHI pricing process for new drugs

More Japan Pricing Reports

Pharmaceutical Pricing, Reimbursement, and Market Access News in the Third Quarter of 2011 by Decision Resources
In the third quarter of 2011, politicians in the United States, Europe, and Japan faced the unpleasant task of having to make substantial budget cuts. ...

Pharmaceutical Pricing & Distribution in Japan, 2010 Update by JustPharmaReports.com
The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing ...

Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011 by Decision Resources
For the international pharmaceutical industry, 2011 began as 2010 ended, with governments in the United States, Europe, and Japan looking to cut costs in the ...

Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry by Decision Resources
Is the world's second largest pharmaceutical market primed for new growth? Although Japan is the second largest pharmaceutical market in the world, regulatory hurdles, a ...

H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009 by Decision Resources
Introduction: The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European ...

See all reports like this >>

More Japan Reports

D&B Country Report: Japan by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Plimsoll Portfolio Analysis - Guard Services (Japan) by Plimsoll Publishing Ltd.
The Plimsoll Portfolio Analysis - Guard Services is a comprehensive evaluation of the Japanese market. The revised and updated 2008 edition analyses the financial performance ...

Plimsoll Portfolio Analysis - Business Consultants (Japan) by Plimsoll Publishing Ltd.
The Plimsoll Portfolio Analysis - Business Consultants is a comprehensive evaluation of the Japanese market. The revised and updated 2008 edition analyses the financial performance ...

Plimsoll Portfolio Analysis - Land Developers (Japan) by Plimsoll Publishing Ltd.
The Plimsoll Portfolio Analysis - Land Developers is a comprehensive evaluation of the Japanese market. The revised and updated 2008 edition analyses the financial performance ...

Japan: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis of Japan, providing an overview of its political, economic and business environment, represented both textually and in graph and ...

See all reports like this >>

Pharmaceutical Pricing and Distribution in Japan: The Keys to Success in the World’s Second Largest Market

Share this report

Other tasks

Research Assistance

Related Markets

Pricing Reports

Free Alert Me service